Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company weekly Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E12.55 EPS (ttm)3.81 Insider Own0.10% Shs Outstand1.64B Perf Week4.67%
Market Cap78.15B Forward P/E10.82 EPS next Y4.42 Insider Trans0.80% Shs Float1.63B Perf Month10.96%
Income6.23B PEG2.83 EPS next Q1.05 Inst Own82.90% Short Float7.59% Perf Quarter0.06%
Sales23.86B P/S3.28 EPS this Y28.70% Inst Trans3.24% Short Ratio9.48 Perf Half Y-4.71%
Book/sh9.81 P/B4.87 EPS next Y3.35% ROA15.60% Target Price56.00 Perf Year-20.81%
Cash/sh17.94 P/C2.66 EPS next 5Y4.43% ROE42.10% 52W Range42.48 - 63.69 Perf YTD-8.10%
Dividend1.64 P/FCF21.55 EPS past 5Y14.50% ROI25.40% 52W High-24.76% Beta0.67
Dividend %3.43% Quick Ratio3.70 Sales past 5Y6.60% Gross Margin71.10% 52W Low12.81% ATR0.94
Employees23300 Current Ratio3.90 Sales Q/Q10.00% Oper. Margin30.70% RSI (14)64.26 Volatility1.71% 2.32%
OptionableYes Debt/Eq1.56 EPS Q/Q286.80% Profit Margin26.00% Rel Volume0.31 Prev Close47.77
ShortableYes LT Debt/Eq1.52 EarningsJul 25 BMO Payout42.70% Avg Volume13.08M Price47.92
Recom2.20 SMA203.89% SMA504.37% SMA200-1.10% Volume3,228,384 Change0.31%
Aug-14-19Upgrade Atlantic Equities Neutral → Overweight $63
May-28-19Initiated Goldman Buy
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
May-03-19Resumed JP Morgan Overweight $62
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-22-19 11:23AM  The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon Zacks
Aug-21-19 02:04PM  Top Stock Reports for Home Depot, Abbott & Bristol-Myers Zacks
12:11PM  The Zacks Analyst Blog Highlights: Walt Disney, AngloGold, Vipshop, Bristol-Myers and Integer Zacks
12:01PM  The Zacks Analyst Blog Highlights: AngloGold, Bristol-Myers, Delta Air, JD.com and M/I Homes Zacks
10:50AM  AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study Zacks
Aug-20-19 02:40PM  Disney Whistleblower's Time in the Sun Zacks
01:54PM  BMY Stock Plus Celgene Will Be A Top 5 Pharma But Should You Buy It? Investor's Business Daily
10:09AM  Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales Zacks
09:15AM  Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Your Portfolio Zacks
09:07AM  4 High Earnings Yield Stocks to Bolster Your Portfolio Zacks
08:55AM  New Strong Buy Stocks for August 20th Zacks
08:54AM  Recession Fears Ebb on Fresh Wave of Stimulus: 5 Top Gainers Zacks
Aug-19-19 10:24AM  Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer Zacks
Aug-17-19 12:22PM  Market Volatility Got You Nervous? The Merger Fund Might Be the Answer Barrons.com
Aug-16-19 09:58AM  REFILE-FDA approves Celgene's bone marrow cancer treatment Reuters
09:00AM  Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC Zacks
Aug-15-19 12:50PM  Seth Klarman's Baupost Boosts Liberty, Reduces eBay GuruFocus.com
07:55AM  Moleculin Completes Enrollment in Early-Stage Cancer Study Zacks
07:48AM  Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth Zacks
Aug-14-19 07:26PM  Seth Klarman Buys XPO Logistics, Exits 3 Positions in 2nd Quarter GuruFocus.com
04:51AM  Stocks - Tilray, Canada Goose, Luckin Coffee Fall Premarket Investing.com
Aug-13-19 10:00AM  Should Value Investors Pick Bristol-Myers Squibb (BMY) Stock? Zacks
Aug-12-19 12:10PM  Bristol-Myers Squibb Stock Has Upside But Mind the Risks InvestorPlace
Aug-09-19 02:03PM  Large Option Trader Buying Nektar Calls Following Stock Crash Benzinga
12:56PM  Why Nektar Therapeutics Stock Is Crashing Today Motley Fool
11:29AM  AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag Zacks
11:11AM  Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss Zacks
10:57AM  Top Research Reports: Bristol-Myers, CME Group, Chubb & More Zacks
10:04AM  Risk-Takers Have a Reasonable Shot with BMY Stock InvestorPlace
Aug-08-19 06:37PM  Nektar Therapeutics stock drops after results MarketWatch
06:11PM  Another Biotech Stock Halted As Manufacturing Issue Comes To Light Investor's Business Daily
02:59PM  Disruptive Health Care ETF Is Good For Your Genes ETF Trends
10:54AM  Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss Zacks
Aug-07-19 01:37PM  Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold Zacks
Aug-06-19 05:26PM  Kahn Brothers' Top 6 Buys in the 2nd Quarter GuruFocus.com
03:45PM  The Top 5 Buys of the Eaton Vance Worldwide Health Sciences Fund GuruFocus.com
03:37PM  Celgene Continues Growing While Waiting for its Acquisition to Close Motley Fool
02:29AM  Fear Around Bristol-Myers Squibb Stock is Starting to Fade InvestorPlace
Aug-05-19 08:11AM  Do Institutions Own Bristol-Myers Squibb Company (NYSE:BMY) Shares? Simply Wall St.
08:00AM  PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility PR Newswire
04:35AM  Big Pharma Sees Pockets of Recent Insider Buying TheStreet.com
Aug-04-19 08:01AM  Notable Insider Buys: AbbVie, Bristol-Myers And More Benzinga
Aug-03-19 06:09PM  Weekly Top Insider Buys Highlight for the Week of Aug. 2 GuruFocus.com
01:15AM  Top Biotech Stocks for February 2019 Investopedia
Aug-02-19 03:53PM  Dodge & Cox Comment on Bristol-Myers Squibb GuruFocus.com
10:04AM  Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down Zacks
07:46AM  4 High Earnings Yield Stocks to Strengthen Your Portfolio Zacks
Aug-01-19 06:07PM  Dodge & Fox's 2nd-Quarter Shareholder Letter GuruFocus.com
10:50AM  Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines Zacks
08:54AM  Is a Beat in Store for Nektar (NKTR) This Earnings Season? Zacks
07:00AM  Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma PR Newswire
Jul-31-19 11:36AM  Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates Zacks
11:32AM  Celgene (CELG) Beats on Q2 Earnings, Raises Revenue Guidance Zacks
10:16AM  Infinity (INFI) Q2 Loss Wider Than Expected, Sales Miss Zacks
Jul-30-19 04:18PM  Why Pharma Giant Merck Expects Its Best Sales Growth In 9 Years Investor's Business Daily
11:23AM  Merck Has a Problem Every Drugmaker Wishes It Had Bloomberg
07:55AM  Celgene stock up after earnings beat MarketWatch
05:37AM  [video]Celgene Posts Strong Second-Quarter Earnings, Raises Guidance TheStreet.com
Jul-29-19 10:10AM  Bristol-Myers Squibb Announces European Commission Approval of Pending Acquisition of Celgene Business Wire
09:10AM  Is Bristol-Myers Squibb (BMY) Stock Undervalued Right Now? Zacks
07:45AM  Celgene Rises as European Commission OKs Merger With Bristol-Myers Investing.com
Jul-27-19 12:41AM  Edited Transcript of BMY earnings conference call or presentation 25-Jul-19 12:30pm GMT Thomson Reuters StreetEvents
Jul-26-19 03:17PM  Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards? Zacks
11:22AM  Senate advances bill to cut the cost of prescriptions Yahoo Finance Video
11:02AM  Bristol-Myers Squibb (BMY) Catches Eye: Stock Jumps 5% Zacks
09:27AM  5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2 Zacks
09:18AM  3 Cancer Treatment Stocks to Buy Right Now Motley Fool
09:15AM  Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now Zacks
09:00AM  Bristol-Myers (BMY) Upgraded to Buy: Here's Why Zacks
08:45AM  3 Reasons Why Bristol-Myers (BMY) Is a Great Growth Stock Zacks
08:39AM  Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment Zacks
06:59AM  Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone for Treatment of Patients with Relapsed and Refractory Multiple Myeloma Business Wire
Jul-25-19 06:23PM  Bristol-Myers Squibb Co (BMY) Q2 2019 Earnings Call Transcript Motley Fool +5.02%
05:09PM  Wall Street Retreats Thursday GuruFocus.com
04:14PM  Two Pharma Stocks Flew On Strong Quarters But Drug Stocks Slipped Investor's Business Daily
03:00PM  5 Things You Need to Know From Bristol-Myers Squibb's Q2 Earnings Update Motley Fool
01:59PM  Bristol-Myers Squibb Earnings: BMY Stock Bounces on Strong Q2, Guidance InvestorPlace
11:16AM  Bristol-Myers earnings beat boosts stock MarketWatch
10:45AM  Bristol-Myers (BMY) Beats on Q2 Earnings & Sales, Raises View Zacks
10:35AM  Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise Reuters
10:32AM  UPDATE 2-Eliquis, Orencia sales propel Bristol-Myers to strong second quarter Reuters
10:18AM  Bristol-Myers Rosy Outlook Trumps Trial Setback as Stock Gains Bloomberg
09:00AM  Pharma Giants Top Second-Quarter Estimates, But Only One Stock Pops Investor's Business Daily
08:59AM  Stocks - Facebook, 3M Rise Premarket; Southwest, Tesla Fall Investing.com
08:53AM  Bristol-Myers Squibb Stock Is Hit by Drug-Trial Data, but Earnings Could Still Triumph Barrons.com
08:28AM  Bristol-Myers tops revenue and profit expectations MarketWatch
08:15AM  Bristol-Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates Zacks
07:21AM  The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug Benzinga
07:00AM  Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise Reuters
06:59AM  Bristol-Myers Squibb Reports Second Quarter Financial Results Business Wire
05:39AM  Bristol-Myers Tops Q2 Profit Forecast, Boosts Guidance as Eliquis Impresses TheStreet.com
03:01AM  Bristol-Myers Squibb Earnings, Revenue Beat in Q2 Investing.com
Jul-24-19 06:07PM  Bristol-Myers Squibb Stock Falls After Results of Cancer Treatment Study Disappoint Barrons.com
05:07PM  Bristol-Myers releases mixed Opdivo lung cancer results Reuters
05:01PM  Bristol-Myers Squibb stock falls on lung cancer drug study result MarketWatch
04:44PM  Bristol-Myers Shares Sputter After Setback for Top Cancer Drug Bloomberg
04:16PM  Bristol-Myers Squibb Provides Update on Part 2 of CheckMate -227 Business Wire
04:16PM  Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint of Overall Survival Business Wire
11:34AM  What To Know About Jounce's Amended Licensing Deal With Celgene Benzinga
09:34AM  Merck (MRK) to Report Q2 Earnings: What's in the Cards? Zacks
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; FameWave Ltd.; and Novartis. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BERTOLINI ROBERT JDirectorJul 31Buy44.7211,000491,92011,397Aug 01 05:06 PM
Samuels Theodore R. IIDirectorMay 16Buy47.295,000236,44027,000May 20 04:36 PM
Santiago Karen MurphyControllerMay 16Sale47.563,065145,7713,066May 20 04:37 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400373,239May 06 04:40 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0011,594025,816Apr 05 04:32 PM
Dubow AdamChief Compliance & Ethics OffiMar 10Option Exercise0.003,735018,240Mar 13 07:41 AM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00173,4190422,683Mar 13 07:40 AM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0062,2550411,547Mar 13 07:39 AM
Biondi PaulSVP, Head of Strategy & BDMar 10Option Exercise0.008,61907,860Mar 13 07:39 AM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0019,9250141,077Mar 13 07:38 AM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0026,568063,652Mar 13 07:37 AM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMar 10Option Exercise0.005,864021,343Mar 13 07:36 AM
Santiago Karen MurphyControllerMar 10Option Exercise0.003,82506,850Mar 13 07:37 AM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0045,1700558,854Mar 13 07:35 AM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,577081,508Mar 13 07:34 AM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0014,180092,626Mar 13 07:42 AM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0015,707014,501Mar 13 07:41 AM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise17.5152,884925,999392,690Mar 04 04:42 PM
LEUNG SANDRAEVP, General CounselFeb 28Option Exercise17.51169,8932,974,826634,478Mar 04 04:42 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerFeb 02Option Exercise0.004,46504,465Feb 05 04:53 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010206,117Dec 04 04:31 PM
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.005920592Oct 04 04:56 PM
Dubow AdamChief Compliance & Ethics OffiSep 03Option Exercise0.00797015,495Sep 05 04:49 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064104,057Sep 05 04:49 PM